Start here if you're new
what it is
PTC makes and sells rare-disease drugs, then layers in royalties, licenses, and milestone payments that can swing results wildly.
how it gets paid
Last year Ptc Therapeutics made $1.7B in revenue.
why it's growing
Revenue grew 114.5% last year. $1.6B matters most because it explains why the stock screens cheap.
what just happened
PTC printed $1.6B in quarterly revenue, but the real question is how much of that was durable.
At a glance
B+ balance sheet — decent shape, but not bulletproof
15/100 earnings predictability — expect surprises
8.1x trailing p/e — the market's not buying it — or you found a deal
-$4.73 fy2024 eps est
$807M fy2024 rev est
xvary composite: 49/100 — below average
What they do
PTC makes and sells rare-disease drugs, then layers in royalties, licenses, and milestone payments that can swing results wildly.
PTC plays where giant drug companies often do not bother: rare diseases with small patient pools and high medical need. That matters because fewer real competitors can mean better pricing, and the company posted a 50.1% operating margin in 2024. If you own this, your edge is not scale. It is knowing a niche well enough to get paid before larger rivals show up.
How they make money
$1.7B
annual revenue · their business grew +114.5% last year
total revenue
$1.7B
+114.5%
The products that matter
legacy rare-disease franchise
Legacy Products
~$1.3B · most of the 2025 base
this group generated roughly $1.3B of the $1.73B reported in 2025. it also explains why 2026 guidance collapses when exclusivity runs out.
the cliff
newly launched commercial asset
Sephience
~$420M · nearly all of 2026 guide
management's $415M–$430M 2026 revenue guide implies Sephience has to carry almost the entire business from here. that concentration is the investment case and the risk case at the same time.
single-asset bridge
withdrawn regulatory candidate
Translarna
feb 2026 NDA withdrawn
PTC withdrew the NDA in February 2026 after FDA feedback. for shareholders, that removed one of the few obvious near-term offsets to a $1.3B revenue hole.
catalyst lost
Key numbers
$109M
long-term debt
Debt → money owed for years → so what: PTC only carries $109M of long-term debt, just 2% of capital, which gives it more room to survive biotech volatility than a heavily borrowed peer.
-$4.73
FY2024 EPS est
EPS → profit per share → so what: the 2024 full-year picture still showed a loss of $4.73 per share, which clashes hard with the recent headline profitability and tells you earnings quality needs scrutiny.
50.1%
operating margin
Operating margin → profit after running the business → so what: 50.1% is huge for a company this small, but you need to know how much came from recurring drug economics versus milestone noise.
8.1x
trailing P/E
P/E → stock price divided by recent profit → so what: 8.1x looks cheap versus the market, but only if you believe the recent profit base is durable.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 10 / 100
- long-term debt $109M (2% of capital)
B+ — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for PTCT right now.
source: institutional data · return history unavailable
What just happened
beat estimates
PTC printed $1.6B in quarterly revenue, but the real question is how much of that was durable.
Latest-quarter revenue rose 642% vs. prior year to $1.6B, and EPS hit $9.45. That sits next to a 2024 full-year loss estimate of $4.73 per share, which is a polite way of saying the income statement has shape-shifted.
$1.6B
revenue
$9.45
eps
50.1%
operating margin
the number that mattered
$1.6B matters most because it explains why the stock screens cheap, and why you should ask whether that quarter was a business trend or a one-off event.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is the legacy-product revenue cliff. PTCT is not dealing with a soft patch. It's replacing a business that just produced $1.73B with one guided to $415M–$430M.
med
Legacy revenue disappears faster than Sephience ramps
2026 revenue guidance of $415M–$430M is roughly 75% below 2025's $1.73B. That tells you the old portfolio was doing most of the work, and it is now rolling off.
If the new launch fails to backfill enough of that gap, the low multiple will not save you. The earnings base itself is shrinking.
med
Sephience becomes the whole thesis
The guide implies Sephience accounts for nearly all of the expected 2026 revenue. That concentration makes execution risk much higher than the headline valuation suggests.
When one asset carries almost the whole commercial bridge, a slow launch hits revenue, sentiment, and multiple all at once.
med
Regulatory setbacks leave the bench thin
PTC withdrew the Translarna NDA in February 2026 after FDA feedback. That removed one of the few visible near-term ways to diversify the revenue base.
A thinner pipeline means less room to absorb commercial misses. The business becomes more binary from here.
A miss versus the $415M guidance floor would tell you the post-cliff business is weaker than management expected. A result near the $430M high end would at least show the bridge is holding.
source: institutional data · regulatory filings · risk analysis
Pay attention to
the number that mattered
Whether 2026 revenue can stay inside the $415M–$430M guide
That range is the first real test of management's reset narrative. Below $415M would weaken the bridge thesis fast.
commercial trend
Sephience launch trajectory
You want early sales to look like a platform, not a placeholder. Right now it is carrying almost the entire 2026 revenue case.
pipeline risk
What replaces Translarna as the next catalyst
The February 2026 withdrawal took one visible option off the board. If nothing else steps up, concentration risk stays high.
next catalyst
Q1 2026 earnings context
The headline quarter matters less than management's language around launch pacing, legacy-product erosion, and how much slack remains in the full-year guide.
Analyst rankings
earnings predictability
15 / 100
in human-speak, analysts do not expect a clean straight line here. product transitions make estimates fragile.
risk rank
3
around the middle of the market on safety. the balance sheet helps, but the revenue base is unstable.
price stability
10 / 100
this stock moves like a biotech in transition because that is exactly what it is.
source: institutional data
Institutional activity
institutional ownership data for PTCT is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$69
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive